

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-10</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
/JDA/	A1	2002/0042535	04/11/02	Gribble <i>et al.</i>	558	429	08/09/01
/JDA/	A2	4,395,423	07/26/83	Neumann	424	304	12/06/79
/JDA/	A3	5,064,823	11/12/91	Lee <i>et al.</i>	514	198	05/01/90
/JDA/	A4	5,603,958	02/18/97	Morein <i>et al.</i>	424	489	05/31/95
/JDA/	A5	6,326,507	12/04/01	Gribble <i>et al.</i>	558	415	06/17/99
/JDA/	A6	6,485,756	11/26/02	Aust <i>et al.</i>	424	725	04/06/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C33	Ambs <i>et al.</i> , "p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells," <i>Nat. Med.</i> , 4(12):1371-1376, 1998.
/JDA/	C34	Andreeff <i>et al.</i> , "PPARgamma nuclear receptor as a novel molecular target in leukemias," 2002 <i>Keystone Symposia</i> , Abstract No. 501, 2002.
/JDA/	C35	Bliard <i>et al.</i> , "Glycosylation of acids under phase transfer conditions. Partial synthesis of saponins," <i>Tetrahedron Lett.</i> , 35:6107-6108, 1994.
/JDA/	C36	Bogdan <i>et al.</i> , "Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10," <i>J. Biol. Chem.</i> , 267:23301-23308, 1992.
/JDA/	C37	Bogdan and Ding, "Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages," <i>J. Leukoc. Biol.</i> , 52(1):119-121, 1992.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-10	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C38	Boolbol <i>et al.</i> , "Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis," <i>Cancer Res.</i> , 56(11):2556-2560, 1996.
	C39	Bore <i>et al.</i> , "The anti-inflammatory triterpenoid methyl 2-cyano-3, 12-dioxoolean 1,9(11)-dien-28-oate methanol solvate hydrate," <i>Acta Crystallorg C.</i> , 58(Pt 3):o199-o200, 2002.
	C40	Brookes <i>et al.</i> , "The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore," <i>Cancer Res.</i> , 67:1793-1802, 2007.
	C41	Chauhan <i>et al.</i> , "The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance," <i>Blood</i> , 103:3158-3166, 2004.
	C42	Chintharlapalli <i>et al.</i> , "2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways," <i>Mol. Pharmacol.</i> , 68:119-128, 2005.
	C43	Clinton <i>et al.</i> , "Steroidal[3,2-c]pyrazoles. II. Androstanes, 19-norandrostanes and their unsaturated analogs," <i>J. Am Chem Soc.</i> , 83:1478-1491, 1961.
	C44	Dean <i>et al.</i> , "Halogenolysis of methyl glycyrrhetate with lithium iodidedimethylformamide," <i>J. Chem. Soc.</i> , 6655-6659, 1965.
	C45	Dezulbe <i>et al.</i> , "Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies," <i>J. Clin. Oncol.</i> , 2007 ASCO Annual Meeting Proceedings, 25(18S):14101, 2007.
	C46	Ding <i>et al.</i> , "Macrophage deactivating factor and transforming growth factors- β_1 , - β_2 and - β_3 inhibit induction of macrophage nitrogen oxide synthesis by IFN- γ^1 ," <i>J Immunol.</i> , 145(3):940-944, 1990.
	C47	Drefahl and Huneck, "Nor-olea-12-enol-17-amin und Olea-12-enol-28-amin," <i>Chem. Ber.</i> , 91:278-281, 1958.
✓	C48	DuBois <i>et al.</i> , "Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors," <i>Gastroenterology</i> , 110:1259-1262, 1996.
/JDA/	C49	Elliot <i>et al.</i> , "The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes," <i>Arthritis Res. Ther.</i> , 5:R285-R291, 2003.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-10	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C50	Elsawa <i>et al.</i> , "Preferential Inhibition of Malignant Cell Growth by CDDO in Waldenstrom Macroglobulinemia," <i>Blood</i> , 108(11):2528, 2006.
	C51	Favaloro, Jr. <i>et al.</i> , "Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages," <i>J Med Chem</i> , 45(22):4801-4805, 2002.
	C52	Hail <i>et al.</i> , "Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)," <i>J. Biol. Chem.</i> , 279:11179-11187, 2004.
	C53	Honda <i>et al.</i> , "A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleanan-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production," <i>Bioorganic & Medicinal Chemistry Letters</i> , 12:1027-1030, 2002.
	C54	Honda <i>et al.</i> , "Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages," <i>Bioorg Med Chem Lett.</i> , 8(19):2711-2714, 1998.
	C55	Honda <i>et al.</i> , "Efficient synthesis of (-)- and (+)-tricyclic compounds with enone functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents," <i>Org Biomol Chem</i> , 1:4384-4391, 2003.
	C56	Honda <i>et al.</i> , "New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages," <i>Bioorg. Med. Chem. Lett.</i> , 7:1623-1628, 1997.
	C57	Honda <i>et al.</i> , "Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages," <i>J. Med. Chem.</i> , 43:1866-1877, 2000.
	C58	Honda <i>et al.</i> , "Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages," <i>Bioorg Med Chem Lett</i> , 9(24):3429-3434, 1999.
↓	C59	Honda <i>et al.</i> , "Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages," <i>J. Med. Chem.</i> , 43:4233-4246, 2000.
/JDA/	C60	Huang <i>et al.</i> , "Inhibition of skin tumorigenesis by Rosemary and its constituents carnosol and ursolic acid," <i>Cancer Res.</i> , 54:701-708, 1994.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-10	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C61	Hyer <i>et al.</i> , "Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells," <i>Cancer Res.</i> , 65:4799-4808, 2005.
	C62	Ikeda <i>et al.</i> , "Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxolean-1,9-dien-28-oic acid," <i>Mol. Cancer Ther.</i> , 3:39-45, 2004.
	C63	Ikeda <i>et al.</i> , "The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance," <i>Cancer Res.</i> , 63:5551-5558, 2003.
	C64	Johansen <i>et al.</i> , "Pharmacology and preclinical pharmacokinetics of the triterpenoid CDDO methyl ester," <i>Proc. Amer. Assoc. Cancer Res.</i> , 44:1728, 2003.
	C65	Johnson <i>et al.</i> , "A plan for distinguishing between some five- and six-membered ring ketones," <i>J. Am Chem. Soc.</i> , 67:1745-1754, 1945.
	C66	Kawamori <i>et al.</i> , "Chemopreventive activity of celecoxib, as specific cyclooxygenase-2 inhibitor, against colon carcinogenesis," <i>Cancer Res.</i> , 58(3):409-412, 1998.
	C67	Kim <i>et al.</i> , "Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxoleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells," <i>Molecular Cancer Therapeutics</i> , 1:177-184, 2002.
	C68	Kircher, "Triterpenes, in organ pipe cactus," <i>Phytochemistry</i> , 19:2707-2712, 1980; Database CAPLUS on STN AN:1981:550946
	C69	Konopleva <i>et al.</i> , "Activation of nuclear transcription factor PPARgamma by the novel triterpenoid CDDO as targeted therapy in breast cancer," <i>2002 Keystone Symposium</i> , Abstract No. 539, 2002.
	C70	Konopleva <i>et al.</i> , "Mechanisms and Activity of PPARgamma-Active Triterpenoids CDDO and CDDO-Me in Leukemias," <i>Blood</i> , 106:2460, 2005.
	C71	Konopleva <i>et al.</i> , "Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias," <i>Mol. Cancer Ther.</i> , 3:1249-1262, 2004.
/JDA/	C72	Konopleva <i>et al.</i> , "PPARgamma Ligand CDDO Induces Apoptosis in Leukemias Via Multiple Apoptosis Pathways," <i>Abstracts of the 44th Annual Meeting of the American Society of Hematology</i> , Abstract No. 2209, 2002.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C73	Konopleva <i>et al.</i> , "PPARgamma Ligands Are Potent Inducers of Apoptosis in Leukemias and Lymphomas," <i>American Society of Hematology 43rd Annual Meeting and Exposition</i> , Abstract No. 501, 2001.
	C74	Konopleva <i>et al.</i> , "PPARgamma Nuclear Receptor as a Novel Molecular Target in Leukemia Therapy," <i>Proc. Amer. Assoc. Cancer Res.</i> , 43:4730, 2002.
	C75	Konopleva <i>et al.</i> , "PPARgamma Nuclear Receptor as a Novel Therapeutic Target in AML," <i>Proc. Amer. Assoc. Cancer Res.</i> , 42:4458, 2001.
	C76	Konopleva <i>et al.</i> , "Suppression of ERK Activation is Required for Triterpenoid Methyl-CDDO-Induced Apoptosis in AML," <i>Blood</i> , 102(11):1404, 2003.
	C77	Konopleva <i>et al.</i> , "Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells," <i>Mol. Cancer Ther.</i> , 5:317-328, 2006.
	C78	Konopleva <i>et al.</i> , "Synthetic triterpenoid CDDO as a novel therapy for resistant breast cancer," <i>Proc. Amer. Assoc. Cancer Res.</i> , 44:2726, 2003.
	C79	Konopleva <i>et al.</i> , "The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells," <i>Leukemia</i> , 19:1350-1354, 2005.
	C80	Konopleva <i>et al.</i> , "The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia," <i>Cancer Res.</i> , 64:7927-7935, 2004.
	C81	Konopleva <i>et al.</i> , "Triterpenoid Methyl-CDDO Is a Potent Inducer of Apoptosis in CD34+ AML Progenitor Cells Via Activation of SAPK Pathways and Inhibition of MAPK Cascades," <i>Blood</i> , 104:2533, 2004.
	C82	Kress <i>et al.</i> , "Triterpenoids Display Single Agent Activity in a Mouse Model of CLL/SBL," <i>Blood</i> , 108(11):2530, 2006.
	C83	Kress <i>et al.</i> , "Triterpenoids Display Single Agent Anti-tumor Activity in a Transgenic Mouse Model of Chronic Lymphocytic Leukemia and Small B Cell Lymphoma," <i>PLoS ONE</i> , 6(e559):1-11, 2007.
/JDA/	C84	Kurinna <i>et al.</i> , "The novel triterpenoid CDDO-Me promotes apoptosis in Gleevec-resistant chronic myeloid leukemia cells by caspase-independent mechanisms," <i>Proc. Amer. Assoc. Cancer Res.</i> , 46:2240, 2005.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-10	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C85	Lapillonne <i>et al.</i> , "Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells," <i>Cancer Res.</i> , 63:5926-5939, 2003.
	C86	Lemieux, "Acylglycosyl Halides. [55] tetra-O-acetyl- α -D-glucopyranosyl bromide," <i>Methods Carbohydr. Chem.</i> , 2:221-222, 1963.
	C87	Ling <i>et al.</i> , "The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling," <i>Cancer Res.</i> , 67:4210-4218, 2007.
	C88	Ling <i>et al.</i> , "The novel triterpenoid CDDO-Me inhibits metastatic murine breast tumor through inhibition of Stat3 signaling," 2007 AACR Annual Meeting, Abstract No. 301, 2007.
	C89	Marnett, "Aspirin and the potential role of prostaglandins in colon cancer," <i>Cancer Res.</i> , 52(20):5575-5589, 1992.
	C90	Melichar <i>et al.</i> , "Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression," <i>Gynecologic Oncology</i> , 93:149-154, 2004.
	C91	Minns <i>et al.</i> , "A novel triterpenoid induces transforming growth factor beta production by intraepithelial lymphocytes to prevent ileitis," <i>Gastroenterology</i> , 127:119-126, 2004.
	C92	Mix <i>et al.</i> , "Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling," <i>Mol. Pharmacol.</i> , 65:309-318, 2004.
	C93	Moncada <i>et al.</i> , "Nitric oxide: physiology, pathophysiology, and pharmacology," <i>Pharmacol. Rev.</i> , 43:109-142, 1991.
	C94	Murphy <i>et al.</i> , "Immunomodulatory Effects of the Triterpenoid CDDO after Allogeneic Bone Marrow Transplantation in Mice: Reduction of Acute Graft-Versus-Host Disease Lethality," <i>Blood</i> , 106:1316, 2005.
✓	C95	Nathan and Xie, "Nitric oxide synthases: roles, tolls, and controls," <i>Cell</i> , 78:915-918, 1994.
/JDA/	C96	Nishino <i>et al.</i> , "Inhibition of the tumor-promoting action of 12-O tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds," <i>Cancer Res.</i> , 48:5210-5215, 1988.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-10	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C97	Ohshima and Bartsch, "Chronic infections and inflammatory process as cancer risk factors: possible role of nitric oxide in carcinogenesis," <i>Mutat. Res.</i> , 305:253-264, 1994.
	C98	Ono <i>et al.</i> , "A convenient procedure for esterification of carboxylic acids," <i>Bull. Chem. Soc. Jpn.</i> , 51:2401-2404, 1978.
	C99	Oshima <i>et al.</i> , "Suppression of intestinal polyposis in Apc ^{Δ716} knockout mice by inhibition of cyclooxygenase 2 (COX-2)," <i>Cell</i> , 87:803-809, 1996.
	C100	Pedersen <i>et al.</i> , "The triterpenoid CDDO induces apoptosis in refractory CLL B cells," <i>Blood</i> , 100:2965-2972, 2002.
	C101	Picard <i>et al.</i> , "The triterpene resinols and related acids, part VI," <i>J. Chem. Soc.</i> , 1045-108, 1939.
	C102	Place <i>et al.</i> , "The novel synthetic triterpenoid, CDDO-imidazolidine, inhibits inflammatory response and tumor growth in vivo," <i>Clin. Cancer Res.</i> , 9:2798-2806, 2003.
	C103	Prescott and White, "Self-promotion? Intimate connections between APC and prostaglandin H synthase-2," <i>Cell</i> , 87:783-786, 1996.
	C104	Reddy <i>et al.</i> , "Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis," <i>Cancer Res.</i> , 56(20):4566-4569, 1996.
	C105	Salvemini <i>et al.</i> , "Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation," <i>J. Clin. Invest.</i> , 93(5):1940-1947, 1994.
	C106	Salvemini <i>et al.</i> , "Nitric oxide activates cyclooxygenase enzymes," <i>Proc. Natl. Acad. Sci. USA</i> , 90(15):7240-7244, 1993.
	C107	Samudio <i>et al.</i> , "2-cyano-3,12 dioxoolean-1,9 diene-28-imidazolidine induces apoptosis in pancreatic cancer via redox-dependent cytoplasmic stress," <i>Proc. Amer. Assoc. Cancer Res.</i> , 46:5899, 2005.
↓	C108	Samudio <i>et al.</i> , "2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolidine (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer," <i>J. Biol. Chem.</i> , 280:36273-36282, 2005.
/JDA/	C109	Samudio <i>et al.</i> , "A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate: direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis," <i>Mol. Pharmacol.</i> , 69:1182-1193, 2006.

25800195.1

EXAMINER: /James Anderson/	DATE CONSIDERED: 11/07/2007
----------------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-10	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C110	Samudio <i>et al.</i> , "A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): Direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis," <i>Proc. Am. Assoc. Cancer Res.</i> , 47: 4693, 2006.
	C111	Samudio <i>et al.</i> , "A Novel Mechanism of Action of Methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): Direct Permeabilization of the Inner Mitochondrial Membrane to Inhibit Electron Transport and Induce Apoptosis," <i>Blood</i> , 106:4462, 2005.
	C112	Samudio <i>et al.</i> , "The novel triterpenoid CDDOme potently synergizes with inhibition of bcl-2 function to induce apoptosis in AML via disruption of intracellular redox homeostasis," <i>Proc. Amer. Assoc. Cancer Res.</i> , 46:4955, 2005.
	C113	Scholz <i>et al.</i> , "Sensitive and specific methods for the determination of CDDO methyl ester in mouse, rat, dog, monkey, and human plasma by LC-tandem mass spectrometry," <i>Proc. Amer. Assoc. Cancer Res.</i> , 4:6321, 2003.
	C114	Seibert and Masferrer, "Role of inducible cyclooxygenase (COX-2) in inflammation," <i>Receptor</i> , 4(1):17-23, 1994.
	C115	Sharpless <i>et al.</i> , "Electrophilic and nucleophilic organoselenium reagents. New routes to alpha, beta-unsaturated carbonyl compounds," <i>J. Am. Chem. Soc.</i> , 95:6137, 1973.
	C116	Sheng <i>et al.</i> , "Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2," <i>J. Clin. Invest.</i> , 99(9):2254-2259, 1997.
	C117	Shishodia <i>et al.</i> , "A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells," <i>Clin. Cancer Res.</i> , 12:1828-1838, 2006.
	C118	Simonsen <i>et al.</i> , "Tetracyclic hydroxy acids," In <i>the Terpenes</i> , Cambridge University, Cambridge, 5:221-285, 1957.
↓	C119	Sporn and Roberts, "Peptide growth factors and inflammation, tissue repair, and cancer," <i>J. Clin. Invest.</i> , 78:329-332, 1986.
/JDA/	C120	Stadheim <i>et al.</i> , "The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells," <i>J. Biol. Chem.</i> , 277:16448-16455, 2002.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C121	Suh <i>et al.</i> , "Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages," <i>Cancer Res.</i> , 58:717-723, 1998.
	C122	Suh <i>et al.</i> , "Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2)," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 39:266, 1998.
	C123	Suh <i>et al.</i> , "Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL," <i>Leukemia</i> , 17:2122-2129, 2003.
	C124	Suh <i>et al.</i> , "Synthetic triterpenoids enhance transforming growth factor β /Smad signaling," <i>Cancer Res.</i> , 63:1371-1376, 2003.
	C125	Suh <i>et al.</i> , "Triterpenoids CDDO and CDDO-Me Down-Regulate FLIP Expression and Sensitize AML Cells to Trail-Induced Apoptosis," <i>American Society of Hematology 43rd Annual Meeting and Exposition</i> , Abstract No. 498, 2001.
	C126	Sun <i>et al.</i> , "The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality," <i>Biology of Blood and Marrow Transplantation</i> , 13:521-529, 2007.
	C127	Tabe <i>et al.</i> , "Chromatin-Mediated Transcriptional Activation with Novel Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) Ligand 2-cyano-1,9-dien-28-oic Acid (CDDO) in Acute Promyelocytic Leukemia Cells," <i>Abstracts of the 44th Annual Meeting of the American Society of Hematology</i> , Abstract No. 2191, 2002.
	C128	Takabe <i>et al.</i> , "Synthesis of lycosyl esters of oleanolic," <i>Carbohydrate Research</i> , 76:101-108, 1979, Database CAPLUS on STN AN:1980:42278.
	C129	Takahashi <i>et al.</i> , "Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane," <i>Cancer Res.</i> , 57:1233-1237, 1997.
	C130	Tamir and Tannebaum, "The role of nitric oxide (NO) in the carcinogenic process," <i>Biochim. Biophys. Acta</i> , 1288:F31-F36, 1996.
✓	C131	Tsao <i>et al.</i> , "DRIP205 co-activator overexpression enhances PPARgamma-mediated differentiation of leukemia cells by CDDO," <i>Proc. Amer. Assoc. Cancer Res.</i> , 46:1855, 2005.
/JDA/	C132	Tsao <i>et al.</i> , "Targeted Induction of Apoptosis in Leukemias by PPARgamma Ligand," <i>American Society of Hematology 43rd Annual Meeting and Exposition</i> , Abstract No. 2381, 2001.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No.: UTSC:652US	Serial No.: 09/998,009
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Marina Konopleva	
		Filing Date: November 28, 2001	Group: 1614
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-10</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
/JDA/	C133	Tsujii and DuBois, "Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2," <i>Cell</i> , 83:493-501, 1995.
	C134	Tsujii <i>et al.</i> , "Cyclooxygenases regulates angiogenesis induced by colon cancer cells," <i>Cell</i> , 93:705-716, 1998.
	C135	Vazquez <i>et al.</i> , "Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation," <i>J. Virol.</i> , 79:4479-4491, 2005.
	C136	Wang <i>et al.</i> , "Synthetic triterpenoid CDDO and its derivatives increase ceramides and are cytotoxic to pediatric acute lymphoblastic leukemia cell lines," <i>Proc. Am. Assoc. Cancer Res.</i> , 47: 4643, 2006.
	C137	Woodley, "Liposomes For Oral Administration of Drugs," <i>Crit. Rev. Therapeutic Drug Carrier System</i> , 2(1):1-18, 1985.
	C138	Yates <i>et al.</i> , "Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes," <i>Mol. Cancer Ther.</i> , 6:154-162, 2007.
	C139	Yates <i>et al.</i> , "Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole," <i>Cancer Res.</i> , 66:2488-2494, 2006.
	C140	Zapata <i>et al.</i> , "CDDO and CDDO-Im Reduce Tumor Burden in a Transgenic Mouse Model of CLL," <i>Blood</i> , 104:3477, 2004.
	C141	Zapata <i>et al.</i> , "Triterpenoids show activity against leukemic cells in a transgenic mouse model of CLL," <i>Proc. Amer. Assoc. Cancer Res.</i> , 46:5179, 2005.
↓	C142	Zhang <i>et al.</i> , "Synthetic triterpenoid CDDO as effective therapy for HER2-expressing resistant breast cancer," <i>Proc. Amer. Assoc. Cancer Res.</i> , Abstract No. 3799, 2004.
/JDA/	C143	Zhang <i>et al.</i> , "The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells," <i>J. Invest. Dermatol.</i> , 123:380-387, 2004.

25800195.1

EXAMINER: /James Anderson/

DATE CONSIDERED: 11/07/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)